EDGAR Filing Documents for 0001654954-21-008249

Form 8-K - Current report:

SEC Accession No. 0001654954-21-008249

Filing Date

2021-07-27

Accepted

2021-07-27 17:25:26

Documents

Period of Report

2021-07-22

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	CURRENT REPORT	azrx8k_jul222021.htm	8-K	43733
2	AMENDED AND RESTATED UNDERWRITING AGREEMENT	ex1-1.htm	EX-1.1	320154
3	FORM OF WAINWRIGHT WARRANT	ex4-1.htm	EX-4.1	137637
4	OPINION OF LOWENSTEIN SANDLER LLP	ex5-1.htm	EX-5.1	13416
5	PRESS RELEASE DATED JULY 22, 2021 (ANNOUNCING PRICING OF OFFERING)	ex99-1.htm	EX-99.1	14870
6	PRESS RELEASE DATED JULY 22, 2021 (ANNOUNCING UPSIZING OF OFFERING)	ex99-2.htm	EX-99.2	14867
7	PRESS RELEASE DATED JULY 27, 2021 (ANNOUNCING CLOSING OF OFFERING)	ex99-3.htm	EX-99.3	16083
8	IMAGE	ex5-1.jpg	GRAPHIC	7171
	Complete submission text file	0001654954-21-008249.txt		572112

Mailing Address 1615 SOUTH CONGRESS AVENUE SUITE 103 DELRAY BEACH FL 33445

Business Address 1615 SOUTH CONGRESS AVENUE SUITE 103 DELRAY BEACH FL 33445 646-699-7855

AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)